A recent analysis of relapsed or refractory multiple myeloma clinical trials concluded that combination and triple regimens are effective first-line treatment strategies.
Xian-Wu Luo and a group of fellow Chinese researchers from Wuhan University performed an updated network meta-analysis because of the complex biological makeup of myeloma.
They studied results from 24 clinical trials to see which treatment combinations provided the best response rates, longest remission times and longest overall survival.
"Results of the meta-analysis showed that the combination of daratumumab, lenalidomide, and dexamethasone had better efficacy results than other regimens in terms of non-response rate, time to progression, and progression-free survival."
This may be an ever changing conclusion as new myeloma therapies are introduced into the clinic, but it's an interesting finding for now.
To find treatment options that are personally relevant to you, try the new HealthTree tool for multiple myeloma patients. Whether you are newly diagnosed, relapsed or refractory to treatment, it will help identify potential treatment options you could discuss with your doctor.
about the author
Myeloma Crowd Editorial Contributor, Nursing student, and cancer advocate.